Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study

Launched by CATHOLIC UNIVERSITY OF BRASÍLIA · Apr 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how physical exercise can help reduce harmful substances in the body called uremic toxins in people with chronic kidney disease (CKD). These toxins can make health problems worse and speed up aging. The researchers want to understand how exercise affects these toxins and overall health in CKD patients, while also considering the diverse backgrounds of people in Brazil. They will track various health factors, including body fitness and nutrition, to see how different types of exercise—like strength training, aerobic training, or a mix of both—impact patients at different stages of kidney disease.

To be eligible for this study, participants need to be adults aged 18 or older who have been diagnosed with chronic kidney disease and meet certain health criteria, such as having ongoing kidney damage. People who regularly exercise, have certain serious health conditions, or who smoke or drink alcohol will not be able to participate. Those who join the study can expect to undergo various assessments to evaluate their health and will be assigned to different exercise groups based on their individual needs. This trial aims to last for 10 years, giving a long-term view of how exercise can benefit kidney disease patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • those diagnosed with chronic kidney disease and presenting persistent albuminuria (\>300mg/g) following KDIGO guidelines;
• • metabolic syndrome {i.e., type 2 diabetes mellitus, arterial hypertension (blood pressure \>180/100mmHg), overweight or obesity, and dyslipidemia};
• • no complications arising from pre-existing clinical metabolic diseases (i.e., diabetic coma, ketoacidosis, hyperosmolarity, and/or uncontrolled diabetes), as evaluated by a nephrologist;
• • absence of neurodegenerative, musculoskeletal, lupus erythematosus, or congenital kidney disease;
• • no apparent cardiovascular complications, such as heart failure, severe arrhythmia, angina, or cerebrovascular disease;
• • no comorbidities that limit performance in physical tests or training;
• • not engaged in exercise programs for at least six months prior to the start of the experimental protocol;
• • no smoking or alcohol consumption behavior;
• • D-dimer values within normal range (220-500 ng/mL FEU)
• Exclusion Criteria:
• • regularly engage in physical exercise,
• • have suffered a stroke in the last 6 months and/or present autoimmune diseases,
• • have unstable cardiac dysfunctions, such as: uncontrolled coronary artery disease, aneurysm at risk of rupture, uncontrolled arrhythmia, uncontrolled hypertension (SBP \> 190 mmHg and/or DBP \> 100 mmHg), heart attack in the last 3 months;
• • infectious conditions, Hb \< 8 in the last routine monthly hemodialysis exam;
• • musculoskeletal pain;
• • fever;
• • resting SpO2 lower than 94%;
• • restriction by the clinical team.